BACKGROUND: Bone metastases are responsible for most of the morbidity associated with metastatic castration-resistant prostate cancer (mCRPC).
Bone-seeking radiopharmaceuticals have been approved for palliation of painful skeletal metastases, but their clinical use is limited by concerns of toxicities both when administered alone and especially when combined with chemotherapy agents.
OBJECTIVE: We investigated whether docetaxel administered to mCRPC patients after treatment with samarium-153-labeled ethylene-diamine-tetra-methylene-phosphonic acid (Sm-EDTMP) has increased toxicity and/or reduced antitumor efficacy.
MATERIALS AND METHODS: Thirty mCRPC patients with skeletal metastases were enrolled. Patients received standard therapy with docetaxel (75 mg/m2 intravenously every 21 days for at least six cycles) on average 6 weeks after Sm-EDTMP (37 MBq/kg). Patients were monitored for the presence of toxicities, and antitumor efficacy was assessed by changes in serum prostate-specific antigen levels. Besides standard descriptive statistical analysis, progression-free survival and overall survival were defined using the Kaplan-Meier method.
RESULTS: Over 80% of the patients showed favorable biochemical responses. Median time to progression was 9.1 months (mean 9.8, 95% confidence interval 7.8-9.9), and median overall survival was 19.9 months (mean 24.5, 95% confidence interval 16.9-22.8); five patients were still alive over 5 years after enrollment. No additional hematological toxicities were observed when docetaxel was administered after Sm-EDTMP other than those expected when administering the agent alone.
CONCLUSION: Prior administration of Sm-EDTMP does not cause additional toxicities for subsequent treatment with docetaxel and does not reduce the antitumor efficacy of the latter. This work justifies further investigations on the possible synergistic effects of combined strategies with the two agents.
Written by:
Borsò E, Boni G, Pastina I, Lorenzoni A, Cianci C, Federici F, Mazzarri S, Orlandini C, Francesca F, Selli C, Ricci S, Rubello D, Mariani G. Are you the author?
Regional Center of Nuclear Medicine, Division of Urology, University of Pisa; Division of Medical Oncology, Division of Urology, University Hospital of Pisa, Pisa; Department of Nuclear Medicine & PET/CT Centre, 'Santa Maria della Misericordia' Hospital, Rovigo, Italy.
Reference: Nucl Med Commun. 2013 Oct 23. Epub ahead of print.
doi: 10.1097/MNM.0000000000000023
PubMed Abstract
PMID: 24157942
UroToday.com mCRPC Treatment Section
